Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wright-Browne, Vance
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer	Active, not recruiting	3	368	Europe, US, RoW	Abemaciclib, Fulvestrant, Placebo	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasm, Neoplasm Metastasis	02/24	02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer	Active, not recruiting	3	866	Europe, Japan, US, RoW	Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasms, Neoplasm Metastasis	06/24	08/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	01/27	04/28
NCT04699630: A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer	Completed	2	121	US	U3-1402, Patritumab Deruxtecan	SCRI Development Innovations, LLC, Daiichi Sankyo	Metastatic Breast Cancer, Locally Advanced Breast Cancer	04/25	04/25
NCT04577963: A Study of Fruquintinib in Combination with Tislelizumab in Advanced Solid Tumors	Terminated	1/2	52	US	Fruquintinib, HMPL-013, Tislelizumab, BGB-A317	Hutchison Medipharma Limited, BeiGene	Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer	06/24	06/24
Wright-Browne, V
NCT04577963: A Study of Fruquintinib in Combination with Tislelizumab in Advanced Solid Tumors	Terminated	1/2	52	US	Fruquintinib, HMPL-013, Tislelizumab, BGB-A317	Hutchison Medipharma Limited, BeiGene	Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer	06/24	06/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Wright-Browne, Vance
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer	Active, not recruiting	3	368	Europe, US, RoW	Abemaciclib, Fulvestrant, Placebo	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasm, Neoplasm Metastasis	02/24	02/26
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer	Active, not recruiting	3	866	Europe, Japan, US, RoW	Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219	Eli Lilly and Company, Eli Lilly and Company	Breast Neoplasms, Neoplasm Metastasis	06/24	08/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)	Recruiting	3	500	Europe, Canada, Japan, US, RoW	Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa	Loxo Oncology, Inc., Eli Lilly and Company	Lymphoma, Mantle-Cell	01/27	04/28
NCT04699630: A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer	Completed	2	121	US	U3-1402, Patritumab Deruxtecan	SCRI Development Innovations, LLC, Daiichi Sankyo	Metastatic Breast Cancer, Locally Advanced Breast Cancer	04/25	04/25
NCT04577963: A Study of Fruquintinib in Combination with Tislelizumab in Advanced Solid Tumors	Terminated	1/2	52	US	Fruquintinib, HMPL-013, Tislelizumab, BGB-A317	Hutchison Medipharma Limited, BeiGene	Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer	06/24	06/24
Wright-Browne, V
NCT04577963: A Study of Fruquintinib in Combination with Tislelizumab in Advanced Solid Tumors	Terminated	1/2	52	US	Fruquintinib, HMPL-013, Tislelizumab, BGB-A317	Hutchison Medipharma Limited, BeiGene	Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer	06/24	06/24